Julie Wang1, Stacie M Jones2, Jacqueline A Pongracic3, Ying Song4, Nan Yang4, Scott H Sicherer4, Melanie M Makhija3, Rachel G Robison3, Erin Moshier5, James Godbold5, Hugh A Sampson4, Xiu-Min Li6. 1. Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: julie.wang@mssm.edu. 2. Department of Pediatrics, Division of Allergy and Immunology, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark. 3. Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Ill. 4. Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY. 5. Department of Preventive Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. 6. Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: xiu-min.li@mssm.edu.
Abstract
BACKGROUND:Food Allergy Herbal Formula-2 (FAHF-2) is a 9-herb formula based on traditional Chinese medicine that blocks peanut-induced anaphylaxis in a murine model. In phase I studies FAHF-2 was found to be safe and well tolerated. OBJECTIVE: We sought to evaluate the safety and effectiveness of FAHF-2 as a treatment for food allergy. METHODS: In this double-blind, randomized, placebo-controlled study 68 subjects aged 12 to 45 years with allergies to peanut, tree nut, sesame, fish, and/or shellfish, which were confirmed by baseline double-blind, placebo-controlled oral food challenges (DBPCFCs), received FAHF-2 (n = 46) or placebo (n = 22). After 6 months of therapy, subjects underwent DBPCFCs. For those who demonstrated increases in the eliciting dose, a repeat DBPCFC was performed 3 months after stopping therapy. RESULTS: Treatment was well tolerated, with no serious adverse events. By using intent-to-treat analysis, the placebo group had a higher eliciting dose and cumulative dose (P = .05) at the end-of-treatment DBPCFC. There was no difference in the requirement for epinephrine to treat reactions (P = .55). There were no significant differences in allergen-specific IgE and IgG4 levels, cytokine production by PBMCs, or basophil activation between the active and placebo groups. In vitro immunologic studies performed on subjects' baseline PBMCs incubated with FAHF-2 and food allergen produced significantly less IL-5, greater IL-10 levels, and increased numbers of regulatory T cells than untreated cells. Notably, 44% of subjects had poor drug adherence for at least one third of the study period. CONCLUSION:FAHF-2 is a safe herbal medication for subjects with food allergy and shows favorable in vitro immunomodulatory effects; however, efficacy for improving tolerance to food allergens is not demonstrated at the dose and duration used.
RCT Entities:
BACKGROUND:Food Allergy Herbal Formula-2 (FAHF-2) is a 9-herb formula based on traditional Chinese medicine that blocks peanut-induced anaphylaxis in a murine model. In phase I studies FAHF-2 was found to be safe and well tolerated. OBJECTIVE: We sought to evaluate the safety and effectiveness of FAHF-2 as a treatment for food allergy. METHODS: In this double-blind, randomized, placebo-controlled study 68 subjects aged 12 to 45 years with allergies to peanut, tree nut, sesame, fish, and/or shellfish, which were confirmed by baseline double-blind, placebo-controlled oral food challenges (DBPCFCs), received FAHF-2 (n = 46) or placebo (n = 22). After 6 months of therapy, subjects underwent DBPCFCs. For those who demonstrated increases in the eliciting dose, a repeat DBPCFC was performed 3 months after stopping therapy. RESULTS: Treatment was well tolerated, with no serious adverse events. By using intent-to-treat analysis, the placebo group had a higher eliciting dose and cumulative dose (P = .05) at the end-of-treatment DBPCFC. There was no difference in the requirement for epinephrine to treat reactions (P = .55). There were no significant differences in allergen-specific IgE and IgG4 levels, cytokine production by PBMCs, or basophil activation between the active and placebo groups. In vitro immunologic studies performed on subjects' baseline PBMCs incubated with FAHF-2 and food allergen produced significantly less IL-5, greater IL-10 levels, and increased numbers of regulatory T cells than untreated cells. Notably, 44% of subjects had poor drug adherence for at least one third of the study period. CONCLUSION:FAHF-2 is a safe herbal medication for subjects with food allergy and shows favorable in vitro immunomodulatory effects; however, efficacy for improving tolerance to food allergens is not demonstrated at the dose and duration used.
Authors: Kamal D Srivastava; Jacob D Kattan; Zhong Mei Zou; Jing Hua Li; Libang Zhang; Sylvan Wallenstein; Joseph Goldfarb; Hugh A Sampson; Xiu-Min Li Journal: J Allergy Clin Immunol Date: 2005-01 Impact factor: 10.793
Authors: A Wesley Burks; Robert A Wood; Stacie M Jones; Scott H Sicherer; David M Fleischer; Amy M Scurlock; Brian P Vickery; Andrew H Liu; Alice K Henning; Robert Lindblad; Peter Dawson; Marshall Plaut; Hugh A Sampson Journal: J Allergy Clin Immunol Date: 2015-02-03 Impact factor: 10.793
Authors: Wyatt W Decker; Ronna L Campbell; Veena Manivannan; Anuradha Luke; Jennifer L St Sauver; Amy Weaver; M Fernanda Bellolio; Eric J Bergstralh; Latha G Stead; James T C Li Journal: J Allergy Clin Immunol Date: 2008-11-06 Impact factor: 10.793
Authors: Kamal D Srivastava; Chunfeng Qu; Tengfei Zhang; Joseph Goldfarb; Hugh A Sampson; Xiu-Min Li Journal: J Allergy Clin Immunol Date: 2009-02 Impact factor: 10.793
Authors: Hans Jürgen Hoffmann; Edward F Knol; Martha Ferrer; Lina Mayorga; Vito Sabato; Alexandra F Santos; Bernadette Eberlein; Anna Nopp; Donald MacGlashan Journal: Curr Allergy Asthma Rep Date: 2016-07 Impact factor: 4.806
Authors: K D Srivastava; Y Song; N Yang; C Liu; I E Goldberg; A Nowak-Węgrzyn; H A Sampson; X-M Li Journal: Clin Exp Allergy Date: 2017-05-15 Impact factor: 5.018
Authors: Bruce J Lanser; Benjamin L Wright; Kelly A Orgel; Brian P Vickery; David M Fleischer Journal: Pediatr Clin North Am Date: 2015-09-07 Impact factor: 3.278
Authors: Nandinee Patel; Daniel C Adelman; Katherine Anagnostou; Joseph L Baumert; W Marty Blom; Dianne E Campbell; R Sharon Chinthrajah; E N Clare Mills; Bushra Javed; Natasha Purington; Benjamin C Remington; Hugh A Sampson; Alexander D Smith; Ross A R Yarham; Paul J Turner Journal: J Allergy Clin Immunol Date: 2021-02-09 Impact factor: 10.793